How were the reported Rapport Therapeutics share prices calculated?

The filing notes that the prices in Column 4 are weighted average prices , with the first sale executed in multiple trades between $24.16 and $25.15 and the second between $25.16 and $25.77 .

Rapport Therapeutics insider updates holdings after Rule 10b5-1 sales

Q: What did the Rapport Therapeutics (RAPP) Form 4 report?

The Form 4 reports that Rapport Therapeutics' Chief Scientific Officer sold shares of the company’s common stock in two transactions on 11/17/2025 and updated their remaining beneficial ownership.

Q: How many Rapport Therapeutics (RAPP) shares were sold and at what prices?

The officer sold 3,156 shares at a weighted average price of $24.8399 and 5,344 shares at a weighted average price of $25.3922 , with both sales reported as dispositions of common stock.

Q: Who is the reporting person in this Rapport Therapeutics Form 4 and what is their role?

The reporting person is identified as an officer of Rapport Therapeutics in the role of Chief Scientific Officer , as indicated in the relationship section of the Form 4.

Q: Does the Form 4 for RAPP involve any derivative securities?

The filing includes a section for Table II - Derivative Securities , but the provided content does not list any specific derivative security transactions, focusing instead on common stock sales.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) reported an insider stock sale by an executive officer. The reporting person, who serves as Chief Scientific Officer, filed a Form 4 showing two open-market sales of common stock on 11/17/2025.

The executive sold 3,156 shares of common stock at a weighted average price of $24.8399, followed by an additional 5,344 shares at a weighted average price of $25.3922. After these transactions, the officer beneficially owns 401,142 shares of Rapport Therapeutics common stock in direct ownership form.

The filing explains that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to predetermined instructions.

Insider Trade Summary

Net Seller: 8,500 shares ($214,091)

Net Sell 2 txns

Insider Bredt David

Role Chief Scientific Officer

Sold 8,500 shs ($214K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,156	$24.8399	$78K
Sale	Common Stock	5,344	$25.3922	$136K

Holdings After Transaction: Common Stock — 406,486 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.16 to $25.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.16 to $25.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Form 4 Insider Transactions: What Each Field Means →

11/18/2025 - 04:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bredt David

(Last)

(First)

(Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON

02110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		S⁽¹⁾		3,156	D	$24.8399⁽²⁾	406,486	D
Common Stock	11/17/2025		S⁽¹⁾		5,344	D	$25.3922⁽³⁾	401,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.16 to $25.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.16 to $25.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the Rapport Therapeutics (RAPP) Form 4 report?

The Form 4 reports that Rapport Therapeutics' Chief Scientific Officer sold shares of the company’s common stock in two transactions on 11/17/2025 and updated their remaining beneficial ownership.

How many Rapport Therapeutics (RAPP) shares were sold and at what prices?

The officer sold 3,156 shares at a weighted average price of $24.8399 and 5,344 shares at a weighted average price of $25.3922, with both sales reported as dispositions of common stock.

How many Rapport Therapeutics shares does the insider still own after these trades?

Following the reported transactions, the reporting person beneficially owns 401,142 shares of Rapport Therapeutics common stock, held in direct ownership.

Was the Rapport Therapeutics (RAPP) insider sale under a Rule 10b5-1 trading plan?

Yes. The explanation states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, which sets predetermined instructions for trading.

Who is the reporting person in this Rapport Therapeutics Form 4 and what is their role?

The reporting person is identified as an officer of Rapport Therapeutics in the role of Chief Scientific Officer, as indicated in the relationship section of the Form 4.

Does the Form 4 for RAPP involve any derivative securities?

The filing includes a section for Table II - Derivative Securities, but the provided content does not list any specific derivative security transactions, focusing instead on common stock sales.